Standard dose cisplatin with rhG-CSF allows sufficient harvesting of PBSC for autotransplantation in patients with ovarian cancer |
| |
Authors: | H. Kurata,K. Takakuwa,N. Yoshiya,S. Kodama,& K. Tanaka |
| |
Affiliation: | Department of Obstetrics and Gynecology, Niigata University School of Medicine, Niigata, Japan |
| |
Abstract: | We have investigated the feasibility of a program of autologous peripheral blood stem cell (PBSC) harvesting and transplantation in patients with ovarian cancer. From four patients, PBSC was collected during hematopoietic recovery following aplasia induced by standard dose cisplatin 70 mg m−2 with etoposide 500 mg m−2 or adriamycin 40 mg m−2 and cyclophosphamide 500 mg m−2 plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) at a dose of 75 µg day−1 given intracutaneously. In apheresed patients, we harvested an average of 2.31 × 105 kg−1 colony-forming unit granulocyte/macrophage (range 0–5.22) per cycle. Low hematologic toxicity was observed during the hematopoietic reconstitution of the four patients subjected to PBSC support with G-CSF (5 µg kg−1 day−1 given by continuous infusion) after high-dose chemotherapy (carboplatin 900 mg m−2 and etoposide 900 mg m−2). The patients were not evaluable for a response because we performed consolidated high-dose chemotherapy. However, no evidence of recurrence has been observed 11.8 months (range 2–19) after high-dose chemotherapy. We can conclude that standard dose cisplatin in combination with etoposide or adriamycin and cyclophosphamide plus rhG-CSF allows sufficient harvesting of PBSC for autotransplantation in patients with ovarian cancer. |
| |
Keywords: | cisplatin G-CSF ovarian cancer PBSC |
|
|